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SulrlrRny. The apparent amount of factor VII as determined in a one-stage test
depends on the type of thromboplastin used: bovine thromboplastin only reacts
with human factor VII' whereas human thromboplastin interacts with
unactivated human factor VII as well. Therefore the ratio factor VII activity as
measured with bovine thromboplastin divided by the factor VII activity as
assessed with human thromboplastin reflects the state of activation of factor VII
in plasma. This approach was used to study the process of cold promoted factor
VII activation and the involvement of different clotting factors therein. It could
be shown that cold promoted activation does not occur in the absence of factors
II and XII and is reduced for about 50% in factor tX deficient plasma' The other
coagulation factors have a minor influence on the process. The results indicate
that the cold promoted factor VII activation is the result of activation by both
activated contact products and thrombin.
Factor VII activation has been described to occur in circulation plasma in different
pathological situations (Meade et aI,I98O; Meade, 1983; van Deijk et al' 7983a, b)' we
therefore used the test described by Hemker et aI (197 6) to measure state of activation of
factor VII in plasma.
Human factor VII is a single chain protein that can be converted to factor VIIa, a two chain
protein. This conversion is associated with an increase in activity as measured in a one-stage
test. The increase, however, is dependent on the type of thromboplastin used to initiate the
reaction. Bovine thromboplastin interacts with human factor VII. but hardly with human
factor VII while human thromboplastin interacts with both human factor VII and factor VII''
The increase in activity with conversion of the single chain into the double chain form will
therefore be much more pronounced when tested with bovine thromboplastin than with
correspondence: Dr M. C. E. van Dam-Mieras, Department of Biochemistry, Limburg 
university
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human thromboplastin. Therefore the state of activation of factor VII in plasma can be
expressed by the ratio: factor Vll6o,,/factor VII6'- (bov:estimated with bovine thromboplas-
tin; hum:estimated with human thromboplastin). This test was used as a tool to investigate
the pathway(s) that lead(s) to cold promoted factor VII activation.
MATERIALS AND METHODS
All chemicals used are of reagent grade; all solutions are made in distilled water; Michaelis
buffer:0'15 u Veronal/acetate, pH 7'4. Hirudin is obtained from Sigma. Thrombin is
obtained from Serva. Chromogenic substrate 52302 is obtained from Kabi Vitrum.
Factor Vll-deficient reagent is prepared as described by Hemker et al (I972).The artificial
reagent contains: 64/ohwman factor X, 72/obovine factor V, 74/ohumanfactor II and,2.25
g/l bovine fibrinogen. The factor VII concentration in the reagent is r.6g%.
Thromboplastins. Human and bovine thromboplastins are prepared as described by van
Dam-Mieras et aI (7984) and stored in small portions at - 20oC. Prior to use thromboplastin
solutions are prewarmed at 3ZoC for minimally 2O min.
Collection and treatment of samples. Blood is collected b5z venipuncture without stasis, in
plastic tubes containing Na-citrate (9 volumes of blood+ 1 volume of 0.109 nr Na-citrate).
The first few millitres of blood are discarded to avoid activation by tissue factor.
Platelet poor plasma is obtained from fresh blood by centrifugation (15 min at 13 000 g).
Platelet free plasma is obtained by centrifugation of platelet poor plasma (20 min at
20 000 g at 4"C) and stored in 1 ml portions at gOoC until use.
Pooled normal plasma is obtained by pooling equal amounts of platelet free plasma from
at least 30 healthy individuals (1 5 males and I 5 females, not using oral contraceptive agents,
average age 30 years) and stored in small portions at - gooc until use.
The following samples are used: pooled human normal plasma; congenital deficient
p lasmas:  v  def ic ient  (n:2) ,  v I I  def ic ient  (n:2) ,  VI I I  def ic ient  (n:6) , IX def ic ient  (n:3) ,  X
deficient (n : 3 ), XI deficient (n:2),XII deficient (n:2).In the results mean values of the data
obtained with the individual factor deficient plasmas are given.
lncubation of plasnm at 4oC.Immediately after thawing, plasma samples are incubated at
4"C in glass or plastic tubes. After 0, 1, 2, 4,24and48 h subsamples are taken from the
incubates and, after dilution with Michaelis buffer, screened for factor VII activation.
During the incubation at 4"C the concentration of fibrinogen in and the pH of the
incubation mixtures were constant.
Determination of factor VII activation Pipette successively into a glass tube: plasma sample
diluted with Michaelis buffer, 0'1 ml: factor VII deficient reagent, 0.1 ml; human or bovine
thromboplastin, 0'1 ml; incubate 30 s at 37"C; CaCIz(33 mlr), 0.1 ml; registrate the clotting
time.
The clotting time obtained with the sample is compared to a reference curve or a rel'erence
table derived from the reference curve using a computer program (Hemker et al, r972).The
reference curve is obtained by measuring the clotting times of a series of dilutions of pooled
normal plasma; the clotting times obtained with these standard plasma dilutions are plotted
against the factor VII concentrations, expressed in per cent of pooled normal plasma,
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according to Hemker et at (1972). Reference curves for both the human and the bovine test
system are constructed.
Prekallikrein activation is measured as described by Alving ef al (1983) using the
chromogenic substrate 52 302.
RESULTS
Fig 1 shows the results obtained when pooled normal plasma is incubated at 4oC in glass and
plastic tubes. The apparent amount of factor VII as measured with a test system using bovine
thromboplastin (we shall call this test system the bovine test system) shows a five-fold
increase during incubation at 4oC. The apparent amount of factor VII as determined in a one-
stage test using human thromboplastin (the human test system) also increases during
incubation at4"C but to a lesser degree (about two-fold). It can also be concluded that,
although the time course of factor VII activation during incubation at 4oC in glass and plastic
tubes is different, the ultimate stage of factor VII activation is very similar in both materials'
This also follows from Fig 2 in which the ratio factor Vllso'/factor VII6'- is plotted'
The involvement of other clotting factors in the process of cold promoted factor VII
activation has been studied by incubating congenital factor deficient plasmas at 4"C, again in
glass and plastic tubes. The results are shown in Figs 3-6. It can be concluded that cold
promoted activation of factor VII only takes place when the factors XIi and of course VII are
present in the plasma. In the absence of factor IX cold promoted activation of factor VII is
reduced to about 50%. In factor VIII deficient plasma the results obtained in glass are similar
Fig l. Activation of factor VII in normal plasma during incubation at 4oc in glass and 
plastic tubes as
measured with bovine and human thromboplastin. I. Glass, bovine thromboplastin; O' 
plastic' bovine
thromboplastin: o, glass, human thromboplastin; o, plastic, human thromboplastin.
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Fig 2' The ratio factor Vll5o"/factor VII6'- in pooled normal plasma during incubation at 4'C in glass (o)
and plastic (r) tubes.
Fig 3. The ratio factor Vll6""/factor VII6,- in congenital deficient plasma during incubation at 4"C in
glass tubes. a, Factor V deficient plasma; l, factor VII deficient plasma; x, factor X deficient plasma,
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Fig 4. The ratio factor Vll6."/factor VII6'- in congenital deficient plasma during incubation at 4oC in
plastic tubes. r, Factor V deficient plasma; l, factor VII deficient plasma; x, factor X deficient plasma.
nouts
Fig 5. The ratio factor Vll6o,/factor VII6.* in congenital deficient plasma during incubation at 4"C in
glass tubes. o, Factor VItr deflcient plasma; *, factor IX deficient plasma; f,, factor XI deficient plasma;
O, factor XII deffcient plasma.
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Fig 6' The ratio factor Vll6.,/factor VII6,. in congenital deficient plasma during incubation at 4oC in
plastic tubes. o, Factor VIII deficient plasma; ft, factor IX deficient plasma; f, factor XI deficient
plasma: O, factor XII deficienrfilasma.
Fig 7. The ratio factor Vllu",/factor VIIr,u. in normal plasma incubated at 4oC in glass tubes in the
presence of different hirudin concentrations. Incubation time: a, 0 h; r, 2 h; o, 4 h; fr,24h: r, 4g h.
Fig 8. The ratio factor Vll6o"/factor VII5,- in normal plasma incubated at 4"C in plastic tubes in the
presenceof difrerenthirudinconcentrat ions. Incubationtime: a,0h; r,  2h;o,4in:*,24h; e,4g h.
CoId Promoted Activation of Factor VII 373
to those obtained with V deficient plasma, but in plastic no activation occurs in factor VIII
deficient plasma. Because congenital factor II deficient plasma is hard to obtain we could only
test one single plasma (results not shown). This plasma showed no VII activation upon
storage at 4oC. However, the initial VIIuou/VIIno- values for this preparation indicated that
some factor VII activation might have occurred during sample preparation.
The results confirm the involvement of the contact phase of blood coagulation in the
process of cold promoted activation, but also point to a role of factor II in this process. In order
to further elucidate the role of factor II, or most probably that of its activation product
thrombin, in the cold-promoted activation of factor VII, normal pooled plasma, supplemented
with various amounts of the thrombin inhibitor hirudin, was incubated at 4oC for 48 h in
both glass and plastic tubes (Figs 7 and 8). The presence of hirudin inhibits the cold-promoted
activation of factor VII in a dose dependent way. Total inhibition is only seen when the
samples are incubated in plastic tubes. In the presence of glass there is a persistent activity
that can be attributed to a thrombin independent cold activation caused by the contact phase
of blood coagulation. The inhibition by hirudin of cold activation in plastic tubes indicates
that thrombin is involved especially if contact activation is (neglectibly) low. The mechanism
by which thrombin activates factor VII cannot be derived from this experiment, of course. As
could be expected, no factor VII activation is observed when the experiments depicted in Figs
7 and 8 are carried out with factor XII deficient plasmas.
In order to track down a possible effect of thrombin upon the contact phase of blood
coagulation, we determined the kallikrein formation during incubation of normal pooled
plasma at 4oC in glass and plastic tubes in the absence and presence of hirudin (Table I). It is
evident from Table I that the presence of hirudin in the incubation mixture does not influence
the generation of kallikrein as measured with the chromogenic substrate 52 302.
Table I. The effect of hirudin on the generation of prekallikrein activity
during incubation of normal plasma at 4oC
Velocity of 52302 hydrolysis
(0 '1AU/min)
Incubate
composition
0 h  4 h  2 4 h
incubation incubation incubation
Buffer (G, P)
Hirudin in buffer (G, P)
Normal plasma+buffer (P)
Normal plasma*hirudin (P)
Normal plasma+bufler (G)
Normal plasma+hirudin (G)
o . t
o ' 1
0 . 3
0 . 3
o.2
o.2
Normal plasma is incubated in the presence or absence of hirudin (final
concentration 100 pg/ml); the prekallikrein generation is measured with
52302. G: incubation in glass: P: incubation in plastic.
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Fig 9. The ratio VIIoo,/VIIr,". in normal plasma incubated at 4oC in glass tubes in the presence of different
thrombin concentrations. t, Normal plasma; r, l0-r u thrombin/ml normal plasma; l, l0-2 u
thrornbinlml normal plasma.
Fig lO. The ratio VIIu"'/VIIr,o^ in normal plasma incubated at 4"C in plastic tubes in the presence of
different thrombin concentrations. a, Normal plasma; e., 10-r U thrombin/ml normal plasma; l, 10-2
U thrombin/ml normal plasma.
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From Figs 9 and 10 it is evident that the presence of thrombin in the incubation mixture
stimulates the cold promoted activation of factor VII in both glass and plastic.
D ISCUSSION
The direct effect of contact activation on the extrinsic coagulation pathway was already
described by Altman & Hemker (1967) who concluded that factor XIIa activated factor VII.
The involvement of both factor IX and factor XiI in the activation of factor ViI (Figs 5 and 6)
has been described in the l iterature (Kisiel et aL,7977; Radcliffe et aL,7977; Seligsohn et al,
I97 8,7979; Gordon et aL,1982; Palmer & Gralnick, 198 3). The role of kall ikrein in the cold-
promoted activation of factor VII (Gjonnaes, 1972a, b) would be indirect through the
generation of factor XII" and factor IXu. Both Seligsohn et aI (I978) and Palmer & Gralnick
(1983) agree that factor IX appears to contribute to approximately 50/6 to the factor VII
activation upon incubation at 4oC. Our results are in agreement with these findings.
The essential role of factor II in the cold-promoted activation of factor VII (Figs 7 and 8)
has not been described before. The effect of factor II could be direct, as factor VII activation by
thrombin has been described (Radcliffe & Nemerson, 1975). By this mechanism trace
amounts of thrombin formed could activate factor VII during the incubation at 4"C. The role
of factor II could also be indirect. for instance via an effect of trace amounts of thrombin on the
contact phase of blood coagulation.
In order to study the effect of factor II on the process of cold promoted activation, factor II
deficiency was approximated by adding the thrombin inhibitor hirudin to normal plasma. As
can be seen in the Figs 7 and 8, the addition of hirudin to the incubation mixture slows down
the cold promoted activation of factor VII in a dose dependent way; total inhibition does not
occur when the incubation takes place in glass. We also tried to approximate factor II
deficiency by adding a factor II specific antiserum to normal plasma. However, this II specific
antiserum also contained small amounts of an inhibitory activity directed against the other
clotting factors. Moreover II neutralization with a II specific antiserum requires an extra
incubation step (30 min at 22"C) possibly interfering with the process of cold promoted factor
VII activation. This problem can only be solved when a monoclonal antibody directed against
thrombin is available.
When, in parallel with factor VII activation, the activation of the contact phase of blood
coagulation is followed by measurement of kallikrein generation with the chromogenic
substrate 52302 (Table I) it can be seen that the presence of hirudin does not influence the
kallikrein generation. Therefore the activation of the contact phase of blood coagulation by
trace amounts of thrombin can be ruled out.
We conclude that the cold promoted activation of factor VII is the result of at least two
parallel processes: (1) an activation offactor VII by activated contact products (a process not
inhibited by hirudin); (2) a direct activation of factor VII by thrombin (a process inhibited by
hirudin). The former process explains the difference in the time course of cold promoted
activation of factor VII in glass and plastic tubes; contact activation is more pronounced on
glass than on plastic surfaces. The latter process explains the effect of hirudin on the cold
promoted activation of factor VII.
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When plasmas from normal individuals are incubated at 4oC all samples show cold-
promoted activation of factor VII upon incubation in glass; only 25lo shows cold promoted
factor VII activation upon incubation in plastic (results not shown). These results can be
explained by the contribution of the contact phase of blood coagulation. We now wonder if
we might speculate that 'cold activators' do occur because of the generation of (trace
amounts of ) thrombin in vivo.
To study the mechanism of cold promoted activation, all congenital factor deficient
plasmas were incubated in both glass and plastic. The fact that several congenital factor
deficient plasmas show a more or less reduced cold promoted activation of factor VII upon
incubation in plastic whereas a normal factor VII activation is reached upon incubation in
glass, most probably must be explained by an impaired thrombin generation in the former
situation (in vivo or in vitro).
The involvement of factor II in the cold-promoted activation could also explain the results
of Donaldson (1984). This author describes that there is not a clear relationship between Cl-
inhibitor deficiency and cold-enhanced plasma coagulation and suggests that events which
initiate the process ofcold-enhanced clotting activation in vitrohave already occurred in vivo.
The equilibria influencing this tendency vary among patients and possibly in any given
patient at different times. This and our own data (van Deijket a\,1983b) make us think that it
might be useful to investigate whether the cold-promoted factor VII activation in vitro can be
used as an early indicator of in vivo changes in the clotting system as a result of pathological
processes, Studies on this subject are in progress.
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